Lowest-Rated StocksLowest-RatedNASDAQ:SION Sionna Therapeutics (SION) Stock Price, News & Analysis $4.90 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.80 -0.11 (-2.14%) As of 10/9/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Sionna Therapeutics Stock (NASDAQ:SION) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sionna Therapeutics alerts:Sign Up Key Stats Today's Range$4.83▼$5.1250-Day Range$4.50▼$51.0452-Week Range$4.01▼$54.97Volume633,560 shsAverage Volume1.48 million shsMarket Capitalization$221.53 millionP/E RatioN/ADividend YieldN/APrice Target$42.33Consensus RatingHold Company Overview Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company is developing small-molecule therapies intended to address the underlying cause of CF by improving the production, processing, stability and function of defective CFTR proteins. Sionna’s research platform is centered on CFTR modulators, including compounds designed to stabilize the CFTR protein’s nucleotide-binding domain 1 (NBD1). Its pipeline has included SION-638, an investigational NBD1 stabilizer intended for use as part of combination treatment regimens. The company’s approach is designed to potentially benefit people with a broad range of CFTR mutations, including patients who may not be adequately served by existing therapies. Sionna conducts drug discovery and clinical development activities for the CF community. As a development-stage company, its investigational products remain subject to clinical testing and regulatory review, and there is no assurance that they will receive approval or become commercially available.AI Generated. May Contain Errors. Read More Sionna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreSION MarketRank™: Sionna Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 317th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingSionna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 11 hold ratings, and 1 sell rating.Upside PotentialSionna Therapeutics has a consensus price target of $42.33, representing about 763.9% upside from its current price of $4.90.Amount of Analyst CoverageSionna Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sionna Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sionna Therapeutics are expected to grow in the coming year, from ($2.54) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sionna Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sionna Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSionna Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.85% of the float of Sionna Therapeutics has been sold short.Short Interest Ratio / Days to CoverSionna Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sionna Therapeutics has recently decreased by 4.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSionna Therapeutics does not currently pay a dividend.Dividend GrowthSionna Therapeutics does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.56 News SentimentSionna Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sionna Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for SION on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sionna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,830,974.00 in company stock.Percentage Held by Insiders5.10% of the stock of Sionna Therapeutics is held by insiders.Percentage Held by InstitutionsSionna Therapeutics has minimal institutional ownership at this time.Read more about Sionna Therapeutics' insider trading history. Receive SION Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sionna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SION Stock News HeadlinesSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceOctober 8 at 8:33 PM | finance.yahoo.comSionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Consensus Price Target of $42.33October 8 at 4:29 AM | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONOctober 6, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONOctober 1, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONSeptember 29, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONSeptember 24, 2026 | prnewswire.comSionna Therapeutics (NASDAQ:SION) Director Sells 3,448,811 Shares of StockSeptember 22, 2026 | insidertrades.comSee More Headlines SION Stock Analysis - Frequently Asked Questions How have SION shares performed this year? Sionna Therapeutics' stock was trading at $41.14 at the beginning of 2026. Since then, SION shares have decreased by 88.1% and is now trading at $4.90. How were Sionna Therapeutics' earnings last quarter? Sionna Therapeutics, Inc. (NASDAQ:SION) announced its earnings results on Thursday, August, 6th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.02. When did Sionna Therapeutics IPO? Sionna Therapeutics (SION) raised $180 million in an IPO on Friday, February 7th 2025. The company issued 10,588,233 shares at $16.00-$18.00 per share. How do I buy shares of Sionna Therapeutics? Shares of SION stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today10/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, SION's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SION Previous SymbolNASDAQ:SION CIK2036042 Webwww.sionnatx.com Phone(617) 819-2020FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Price Target for Sionna Therapeutics$42.33 High Price Target$63.00 Low Price Target$5.00 Potential Upside/Downside+763.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.94% Return on Assets-31.08% Debt Debt-to-Equity RatioN/A Current Ratio20.05 Quick Ratio20.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book0.71Miscellaneous Outstanding Shares45,210,000Free Float42,906,000Market Cap$221.53 million OptionableN/A Beta1.00 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SION) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
